 |
 |
|
 |
||
 |
 |
|
 |
|
|
Last Updated: 3/21/2007
| James L. Mohler, MD
Chair, Urologic Oncology, Roswell Park Cancer Inst |  |
Research Interests
James L. Mohler, MD
Chair, Department of Urologic Oncology
Leader, Prostate Program
Professor of Oncology
Roswell Park Cancer Institute
Professor, Department of Urology
School of Medicine and Biomedical Sciences
University at Buffalo, State University of New York
Dr. James L. Mohler joined the staff of Roswell Park Cancer Institute (RPCI) in May 2003, as Chair of the Department of Urologic Oncology. He also is Leader of the Prostate Program. Dr. Mohler also serves as Professor of Urology at the University at Buffalo (UB) School of Medicine and Biomedical Sciences.
Dr. Mohler came to RPCI after 16 years at the University of North Carolina (UNC), and UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, where he served as Associate Professor of Surgery, Associate Professor of Pathology and Laboratory Medicine, and Director of the UNC Prostate Cancer Research Program.
Dr. Mohler earned his medical degree from the Medical College of Georgia, Augusta, and competed an internship in Internal Medicine at Duke University Medical Center, Durham, NC, residency training in Surgery and Urology at the University of Kentucky Medical Center, Lexington, and a research fellowship in Urologic Oncology at The Johns Hopkins University School of Medicine, Baltimore, MD.
Dr. Mohler is licensed by New York State and North Carolina and is a Diplomate of the National Board of Medical Examiners and the American Board of Urology and a Fellow with the American College of Surgeons. He also currently maintains his academic appointments of Associate Professor of Surgery and Associate Professor of Pathology and Laboratory Medicine at UNC.
Dr. Mohler’s research interests focus on understanding the role of the androgen receptor in the growth of prostate cancer. The research laboratory works exclusively on prostate cancer with an emphasis on the role of the androgen receptor in the regulation of prostate cancer growth with particular emphasis on 1) the mechanism of recurrent growth after androgen deprivation therapy and 2) racial differences in the androgen axis. The lab uses image analysis, immunohistochemistry, LASER capture microdissection, molecular analyses (denaturing gradient gel electrophoresis, SSCP and direct sequencing) and mass spectrometry to analyze banked human tissues (androgen-stimulated, recurrent and a series of prostate biopsies performed before and after castration in men with advanced prostate cancer), tumors from the androgen-dependent CWR22 human prostate cancer xenograft and various androgen-dependent and recurrent CaP cell lines. Dr. Mohler’s lab has demonstrated recently that “androgen-independent” is probably androgen-dependent, a finding that should result in a paradigm change and novel therapies directed at the androgen receptor and its ligands in men with advanced CaP that have failed standard androgen deprivation therapy. In CaP that has recurred during androgen deprivation therapy, tissue levels of testosterone and dihydrotestosterone are sufficient for androgen receptor activation, the androgen receptor protein is expressed at high levels and the classic androgen-regulated gene, prostate-specific antigen (PSA), is expressed. In addition, castration-recurrent prostate cancer changes its 5-a-reducing activity from type I to type II which suggests a possible role for bi-specific 5-a-reductase inhibitors to induce re-remission. The research is conducted by in collaboration with two laboratories at UNC (Drs. Frank French and Betty Wilson; and Dr. Tal Kafri), the NIEHS Mass Spectrometry Facility (Dr. Ken Tomer) and four laboratories at RPCI (Drs. Candace Johnson, Gary Smith, Sergio Onate and Barbara Foster). This research program is funded primarily by the National Cancer Institute (a program project entitled “Prostate Cancer: Transition to Androgen Independence) and the Department of Defense Prostate Cancer Research Program (a novel idea award entitled “Prevention of Development of Recurrent Growth of Prostate Cancer” and the UNC Prostate Cancer Consortium entitled “Racial Differences in Prostate Cancer: Role of Health Care Interaction and Host and Tumor Biology”).
Clinically, he is studying the application of robot-assisted surgery for prostate removal, evaluating the role of observation for some men with prostate cancer and testing novel treatments for advanced prostate cancer.
Dr. Mohler is Chair of the NCCN Prostate Cancer Guideline Committee, Vice-President of the Society for Basic Urologic Research and Vice Chair of the Urology Committee of the Cancer and Leukemia Group B (CALGB) and is a member of the American Medical Association, American Urological Association, American Association for the Advancement of Science, American Association for Cancer Research, American Urological Association and the American College of Surgeons.
Dr. Mohler has authored or co-authored more than 100 publications and book chapters and serves on the editorial board of The prostate and Journal of Robotic Surgery and is a reviewer for the American Journal of Epidemiology, American Journal of Epidemiology, Analytical and Quantitative Cytology and Histology , Cancer, Cancer Research, Cell and Tissue Research, Clinical and Experimental Metastasis, Clinical Cancer Research, Cytometry, Journal of Urology,
The Prostate, Urology and Urologic Oncology.
Publications
Bailey DE, Mishel MH, Belyea M, Stewart JL, Mohler JL. Uncertainty intervention for watchful waiting in prostate cancer. Cancer Nurs 2004;27:339-346.
Marks L, Kojima M, Demarzo A, Heber D, Bostwick D, Qian J, Dorey F, Veltri R, Mohler J, Partin A. Prostate cancer in native Japanese and Japanese-American men. Urology 2004;64:765-771.
Singh SS, Kim D, Ford OH, 3rd, Mohler JL. Automated nuclear analysis of prostate cancer and benign prostate hyperplasia. Proceeding of Biomedical Engineering, IASTED International Conference on Software Engineering, 2005; Innsbruck, Austria. ACTA Press, 95-98.
Singh S, Kim D, Mohler JL. Java web start based software for automated quantitative nuclear analysis of prostate cancer and benign prostate hyperplasia. Bio Med Eng Online 2005;4:31.
Liu Y, Majumder S, McCall W, Sartor C, Mohler JL, Gregory CW, Earp HS, Whang YE. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer. Cancer Res 2005;65:3404-9.
Titus MA, Gregory CW, Ford OH III, Lazier CB, Schell MJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
Titus MA, Schell MJ, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 2005;11:4653-7.
Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005; 65: 6640-50.
Gregory CW, Whang YE, McCall W, Fei X, Liu Y, Ponguta LA, French FS, Wilson EM, Mohler JL, Earp HS. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res (In Press).
Mahajan N, Whang YE, Mohler JL, Earp HS. Activated tyrosine kinase Ack1 promotes prostate tumorigenesis: role of Ack1 in polyubiquitination of tumor suppressor wwox. Cancer Research (In Press).
E-mail: james.mohler@roswellpark.org
Telephone: (716)845-8433
FAX: (716)845-3300
Address: Elm & Carlton Streets Buffalo, NC 14057
